Who are Gamma Interferon 1b's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gm-Csf, Interleukin 2, IL-2 (interleukin 2), Interferon beta 1a, oral doxycycline, PUVA (8MOP + UVA) + IFN, Early receiving G-CSF group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gamma-interferon-1b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Gamma Interferon 1b — Competitive Intelligence Brief

Gamma Interferon 1b (Gamma Interferon 1b) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine; Interferon. Area: Immunology; Infectious Disease.

marketed Cytokine; Interferon Interferon-gamma receptor (IFNGR) Immunology; Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Gamma Interferon 1b (Gamma Interferon 1b) — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Gamma Interferon 1b (IFN-γ-1b) activates macrophages and enhances immune cell function to boost innate and adaptive immunity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gamma Interferon 1b TARGET	Gamma Interferon 1b	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	Cytokine; Interferon	Interferon-gamma receptor (IFNGR)
Gm-Csf	gm-csf	Pfizer	marketed	cytokine	GM-CSF receptor	1991-01-01
Interleukin 2	Interleukin 2	Assistance Publique - Hôpitaux de Paris	marketed	Cytokine immunotherapy	IL-2 receptor (CD25)
IL-2 (interleukin 2)	IL-2 (interleukin 2)	King's College London	marketed	Cytokine	IL-2 receptor (IL-2R)
Interferon beta 1a, oral doxycycline	Interferon beta 1a, oral doxycycline	Louisiana State University Health Sciences Center Shreveport	marketed	Cytokine + tetracycline antibiotic combination	Interferon-beta receptor (IFNBR); doxycycline targets bacterial ribosomes and matrix metalloproteinases
PUVA (8MOP + UVA) + IFN	PUVA (8MOP + UVA) + IFN	Madrilenian Group of Cutaneous Lymphomas	marketed	Photochemotherapy + cytokine combination
Early receiving G-CSF group	Early receiving G-CSF group	Department of Medical Services Ministry of Public Health of Thailand	marketed	Cytokine; Hematopoietic growth factor	G-CSF receptor (GCSFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine; Interferon class)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
Pfizer · 1 drug in this class
Royal Marsden NHS Foundation Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gamma Interferon 1b — Competitive Intelligence Brief. https://druglandscape.com/ci/gamma-interferon-1b. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab